摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-甲基-3-噻吩甲酸 | 1918-78-1

中文名称
2-甲基-3-噻吩甲酸
中文别名
2-甲基噻吩-3-羧酸;2-甲基噻吩-3-甲酸
英文名称
2-methylthiophene-3-carboxylic acid
英文别名
2-methyl-3-thiophenecarboxylic acid
2-甲基-3-噻吩甲酸化学式
CAS
1918-78-1
化学式
C6H6O2S
mdl
——
分子量
142.178
InChiKey
YJZOPBSZDIBXBG-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    106-111 °C
  • 沸点:
    271.5±20.0 °C(Predicted)
  • 密度:
    1.319±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.5
  • 重原子数:
    9
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.17
  • 拓扑面积:
    65.5
  • 氢给体数:
    1
  • 氢受体数:
    3

安全信息

  • 海关编码:
    2934999090
  • 危险性防范说明:
    P261,P280,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H332,H335
  • 储存条件:
    室温且干燥

SDS

SDS:78e6c3e3167735e0558e5db53c8e748a
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 2-Methylthiophene-3-carboxylic acid
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 2-Methylthiophene-3-carboxylic acid
CAS number: 1918-78-1

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C6H6O2S
Molecular weight: 142.2

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, sulfur oxides.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量
    • 1
    • 2

反应信息

  • 作为反应物:
    描述:
    2-甲基-3-噻吩甲酸硼烷四氢呋喃络合物甲醇 作用下, 以 四氢呋喃 为溶剂, 反应 2.0h, 生成 (2-甲基-3-噻吩基)甲醇
    参考文献:
    名称:
    [EN] NOVEL INDOLE AND PYRROLOPYRIDINE AMIDES
    [FR] NOUVEAUX AMIDES D'INDOLE ET DE PYRROLOPYRIDINE
    摘要:
    本发明涉及式(I)的吲哚和吡咯吡啶酰胺衍生物,其中R1、R2、R3、U、V、W、X、Y、Z和环A如描述中所述,以及它们的制备方法,其药学上可接受的盐,以及它们作为药物的用途,含有式(I)的一个或多个化合物的药物组合物,特别是它们作为促进睡眠激素受体拮抗剂的用途。
    公开号:
    WO2012114252A1
  • 作为产物:
    描述:
    参考文献:
    名称:
    Steinkopf; Jacob, Justus Liebigs Annalen der Chemie, 1935, vol. 515, p. 273,277
    摘要:
    DOI:
点击查看最新优质反应信息

文献信息

  • Cu/Fe Catalyzed Intermolecular Oxidative Amination of Benzylic C−H Bonds
    作者:Cong Liu、Qi Zhang、Hongbo Li、Shuangxi Guo、Bin Xiao、Wei Deng、Lei Liu、Wei He
    DOI:10.1002/chem.201600107
    日期:2016.4.25
    We report a Cu/Fe co‐catalyzed Ritter‐type C−H activation/amination reaction that allows efficient and selective intermolecular functionalization of benzylic C−H bonds. This new reaction is featured by simple reaction conditions, readily available reagents and general substrate scope, allowing facile synthesis of biologically interesting nitrogen containing heterocycles. The Cu and Fe salts were found
    我们报告了一种铜/铁共催化的Ritter型CH活化/胺化反应,该反应可实现苄基CH键的高效和选择性分子间官能化。该新反应的特征在于简单的反应条件,容易获得的试剂和一般的底物范围,从而可以轻松合成生物学上令人感兴趣的含氮杂环。发现铜盐和铁盐在这种协同催化中起不同的作用。
  • [EN] INHIBITORS OF EZH2<br/>[FR] INHIBITEURS DE L'EZH2
    申请人:LILLY CO ELI
    公开号:WO2017035060A1
    公开(公告)日:2017-03-02
    The present invention relates to compounds that inhibit activity of the histone lysine methyltransferase, Enhancer of Zeste Homolog 2 (EZH2), pharmaceutical compositions comprising the compounds, and methods of using the compounds to treat cancer, such as hematologic and solid tumors.
    本发明涉及抑制组蛋白赖氨酸甲基转移酶Enhancer of Zeste Homolog 2(EZH2)活性的化合物,包括这些化合物的药物组合物,以及使用这些化合物治疗癌症,如血液学和实体肿瘤的方法。
  • Activation of Aryl Carboxylic Acids by Diboron Reagents towards Nickel‐Catalyzed Direct Decarbonylative Borylation
    作者:Xi Deng、Jiandong Guo、Xiaofeng Zhang、Xiaotai Wang、Weiping Su
    DOI:10.1002/anie.202106356
    日期:2021.11.8
    A Ni-catalyzed direct decarbonylative borylation of aryl carboxylic acids with B2cat2 has been established. B2cat2 serves as a borylating agent, but also activates the carboxylic acid substrate towards decarbonylative coupling, playing a dual role in this reaction. A combination of experimental and computational studies reveals that the reaction proceeds through a hitherto unknown concerted decarbonylation
    已经建立了镍催化的芳基羧酸与 B 2 cat 2 的直接脱羰硼酰化反应。B 2 cat 2作为硼酸化剂,但也活化羧酸底物以进行脱羰偶联,在该反应中发挥双重作用。实验和计算研究的结合表明,该反应通过迄今为止未知的协同脱羰和还原消除步骤进行。
  • [EN] 3, 4-DISUBSTITUTED 1H-PYRAZOLE COMPOUNDS AND THEIR USE AS CYCLIN DEPENDENT KINASES (CDK) AND GLYCOGEN SYNTHASE KINASE-3 (GSK-3) MODULATORS<br/>[FR] COMPOSES 1H-PYRAZOLE 3,4-DISUBSTITUES ET LEUR UTILISATION EN TANT QUE KINASES DEPENDANT DES CYCLINES (CDK) ET MODULATEURS DE LA GLYCOGENE SYNTHASE KINASE-3 (GSK-3)
    申请人:ASTEX TECHNOLOGY LTD
    公开号:WO2005012256A1
    公开(公告)日:2005-02-10
    The invention provides compounds of the formula (0) or salts or tautomers or N-oxides or solvates thereof for use in the prophylaxis or treatment of disease states and conditions such as cancers mediated by cyclin-dependent kinase and glycogen synthase kinase-3. Formula (0). In formula (0): X is a group R1-A-NR4- or a 5- or 6-membered carbocyclic or heterocyclic ring; A is a bond, S02, C=O, NRg(C=O) or O(C=O) wherein Rg is hydrogen or C1-4 hydrocarbyl optionally substituted by hydroxy or C1-4 alkoxy; Y is a bond or an alkylene chain of 1, 2 or 3 carbon atoms in length; R1 is hydrogen; a carbocyclic or heterocyclic group having from 3 to 12 ring members; or a C1-8 hydrocarbyl group optionally substituted by one or more substituents selected from halogen (e.g. fluorine), hydroxy, C1-4 hydrocarbyloxy, amino, mono- or di-C1-4 hydrocarbylamino, and carbocyclic or heterocyclic groups having from 3 to 12 ring members, and wherein 1 or 2 of the carbon atoms of the hydrocarbyl group may optionally be replaced by an atom or group selected from 0, S, NH, SO, S02; R2 is hydrogen; halogen; C1-4 alkoxy (e.g. methoxy); or a C1-4 hydrocarbyl group optionally substituted by halogen (e.g. fluorine), hydroxyl or C1-4 alkoxy (e.g. methoxy); R3 is selected from hydrogen and carbocyclic and heterocyclic groups having from 3 to 12 ring members; and R4 is hydrogen or a C1-4 hydrocarbyl group optionally substituted by halogen (e.g. fluorine), hydroxyl or C1-4 alkoxy (e.g. methoxy).
    该发明提供了以下式(0)的化合物或其盐或互变异构体或N-氧化物或其溶剂合物,用于预防或治疗由细胞周期依赖性激酶和糖原合成酶-3介导的癌症等疾病状态和病症。在式(0)中:X是一个基团R1-A-NR4-或一个5-或6-成员的碳环或杂环;A是一个键,S02,C=O,NRg(C=O)或O(C=O),其中Rg是氢或C1-4烃基,可以选择性地被羟基或C1-4烷氧基取代;Y是一个键或一个由1、2或3个碳原子组成的烷基链;R1是氢;一个具有3到12个环成员的碳环或杂环基团;或一个C1-8烃基,可以选择性地被卤素(如氟)、羟基、C1-4烷氧基、氨基、单或双C1-4烃基氨基以及具有3到12个环成员的碳环或杂环基团取代,其中烃基的1或2个碳原子可以选择性地被从0、S、NH、SO、S02中选择的原子或基团所取代;R2是氢;卤素;C1-4烷氧基(如甲氧基);或一个C1-4烃基,可以选择性地被卤素(如氟)、羟基或C1-4烷氧基(如甲氧基)取代;R3从氢和具有3到12个环成员的碳环或杂环基团中选择;R4是氢或一个C1-4烃基,可以选择性地被卤素(如氟)、羟基或C1-4烷氧基(如甲氧基)取代。
  • Substituted Indoles
    申请人:AbbVie Inc.
    公开号:US20170174688A1
    公开(公告)日:2017-06-22
    The invention provides for compounds of formula (I) wherein R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by SUV420H1. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).
    该发明提供了以下式(I)的化合物 其中R 1 ,R 2 ,R 3 ,R 4 ,R 5 和R 6 具有规范中定义的任何值,以及其药学上可接受的盐,这些化合物在治疗由SUV420H1介导和调节的疾病和症状中作为药剂是有用的。还提供了由一个或多个式(I)化合物组成的药物组合物。
查看更多

同类化合物

阿罗洛尔 阿替卡因 阿克兰酯 锡烷,(5-己基-2-噻吩基)三甲基- 邻氨基噻吩(2盐酸) 辛基5-(1,3-二氧戊环-2-基)-2-噻吩羧酸酯 辛基4,6-二溴噻吩并[3,4-b]噻吩-2-羧酸酯 辛基2-甲基异巴豆酸酯 血管紧张素IIAT2受体激动剂 葡聚糖凝胶LH-20 苯螨噻 苯并[c]噻吩-1-羧酸,5-溴-4,5,6,7-四氢-3-(甲硫基)-4-羰基-,乙基酯 苯并[b]噻吩-2-胺 苯并[b]噻吩-2-胺 苯基-[5-(4,4,5,5-四甲基-[1,3,2]二氧杂硼烷-2-基)-噻吩-2-基亚甲基]-胺 苯基-(5-氯噻吩-2-基)甲醇 苯乙酸,-α--[(1-羰基-2-丙烯-1-基)氨基]- 苯乙酰胺,3,5-二氨基-a-羟基-2,4,6-三碘- 苯乙脒,2,6-二氯-a-羟基- 腈氨噻唑 聚(3-丁基噻吩-2,5-二基),REGIOREGULAR 硝呋肼 硅烷,(3-己基-2,5-噻吩二基)二[三甲基- 硅噻菌胺 盐酸阿罗洛尔 盐酸阿罗洛尔 盐酸多佐胺 甲酮,[5-(1-环己烯-1-基)-4-(2-噻嗯基)-1H-吡咯-3-基]-2-噻嗯基- 甲基5-甲酰基-4-甲基-2-噻吩羧酸酯 甲基5-乙氧基-3-羟基-2-噻吩羧酸酯 甲基5-乙基-3-肼基-2-噻吩羧酸酯 甲基5-(氯甲酰基)-2-噻吩羧酸酯 甲基5-(氯乙酰基)-2-噻吩羧酸酯 甲基5-(氨基甲基)噻吩-2-羧酸酯 甲基5-(4-甲氧基苯基)-2-噻吩羧酸酯 甲基5-(4-甲基苯基)-2-噻吩羧酸酯 甲基5-(1,3-二氧戊环-2-基)-2-噻吩羧酸酯 甲基4-硝基-2-噻吩羧酸酯 甲基4-氰基-5-(4,6-二氨基吡啶-2-基)偶氮-3-甲基噻吩-2-羧酸酯 甲基4-氨基-5-(甲硫基)-2-噻吩羧酸酯 甲基4-{[(2E)-2-(4-氰基苯亚甲基)肼基]磺酰}噻吩-3-羧酸酯 甲基4-(氯甲酰基)-3-噻吩羧酸酯 甲基4-(氨基磺酰基氨基)-3-噻吩羧酸酯 甲基3-甲酰氨基-4-甲基-2-噻吩羧酸酯 甲基3-氨基-5-异丙基-2-噻吩羧酸酯 甲基3-氨基-5-(4-溴苯基)-2-噻吩羧酸酯 甲基3-氨基-4-苯基-5-(三氟甲基)-2-噻吩羧酸酯 甲基3-氨基-4-氰基-5-甲基-2-噻吩羧酸酯 甲基3-氨基-4-丙基-2-噻吩羧酸酯 甲基3-[[(4-甲氧基苯基)亚甲基氨基]氨基磺酰基]噻吩-2-羧酸酯